Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 301–400 of 1,014
APOEε4 potentiates the relationship between amyloid-β and tau pathologies
Therriault, J., Benedet, A. L., Pascoal, T. A., Mathotaarachchi, S., Savard, M., Chamoun, M., Thomas, E., Kang, M. S., Lussier, F., Tissot, C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0688-6 · Cited by 105
Leoutsakos, J.-M. S., Yan, H., Anderson, W. S., Asaad, W. F., Baltuch, G., Burke, A., Chakravarty, M. M., Drake, K. E., Foote, K. D., Fosdick, L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180121 · Cited by 104
Self-citationCan we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Tse, K., & Herrup, K. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14079 · Cited by 105
“…antibodies against amyloid have repeatedly failed to deliver beneficial neurological outcomes in clinical trials, despite their efficiency in amyloid clearance – with solanezumab and bapineuzumab being only the latest examples (Doody et al. 2014; Salloway et al. 2014; Abbott and Dolgin 2016).”
BackgroundA phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia
Weekman, E. M., & Wilcock, D. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150759 · Cited by 108
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
“In the first two trials (studies 301 and 302), the modified intention-to-treat population included 1090 carriers and 1114 non-carriers [50].”
BackgroundPET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. S., Bateman, R. J., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
“The presumption that these biomarker effects represented a clinically relevant treatment effect, however, was called into question when no clinical benefit was found in the phase III trials, despite hints that biomarkers were impacted by therapy [19].”
BackgroundSelf-citationMedical Comorbidity in Alzheimer’s Disease: A Nested Case-Control Study
Wang, J., Wu, Y.-J., Tee, B. L., & Lo, R. Y. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170786 · Cited by 112
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D., Carmona‐Iragui, M., Clarimon, J., Blesa, R., Lleó, A., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 109
“The unexpected finding of cortical atrophy (without clinical deterioration) seen in previous active (AN1792 trial) [46] and passive (solanezumab [47] and bapineuzumab [48]) immunization trials is better explained if we consider the pathologic thickening associated with brain amyloidosis [11].”
BackgroundFolch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 97
“Bapineuzumab es un anticuerpo monoclonal humanizado contra el extremo N-terminal de la proteína (cid:2) A (A (cid:2) 1-5), mientras que solane-zumab es un anticuerpo monoclonal humanizado dise˜nado para unirse la porción central de la proteína (cid:2) A (A (cid:2) 12-28) 59,60 .”
Hao, L., Wang, X., Zhang, L., Xing, Y., Guo, Q., Hu, X., Mu, B., Chen, Y., Chen, G., Cao, J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170347 · Cited by 109
“However, current treatment studies with new drugs against amyloid- and tau pathology at the mild or moderate dementia stage of the illness have failed [2, 3], suggesting that treatment needs to be applied as early as the preclinical stage of the disease [4].”
Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 101
Hoogmartens, J., Cacace, R., & Van Broeckhoven, C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 104
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Uncovering the Mechanisms Responsible for Why Language Learning May Promote Healthy Cognitive Aging
Antoniou, M., & Wright, S. M. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.02217 · Cited by 125
“Pharmacological trials have had little success in slowing down the progression of Alzheimer’s disease (Salloway et al., 2014).”
BackgroundSun, L., Cho, H.-J., Sen, S., Arango, A. S., Huynh, T. T., Huang, Y., Bandara, N., Rogers, B. E., Tajkhorshid, E., & Mirica, L. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05470 · Cited by 98
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 111
“…week 78 (SE) 0.5 mg/Kg: 3.3 ± 0.1 PL: 3.0 ± 0.2 LS mean change (SE) at week 71 BAPI: 0.001 (0.0207) PL: 0.102 (0.0264) 0.5 mg/Kg: 103 PL: 1 no ARIA-H observed Salloway 2014 [25] NCT 00667810 terminated FP: 2008 Phase III RCT 885 mild to moderate AD (NINCDSADRDA) MMSE 16–26 MRI consistent with AD…”
InfluentialCogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 93
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
The Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
“Unfortunately, phase three clinical trials have shown no difference in cognitive abilities of Alzheimer’s disease patients treated with the antibody compared with controls (149).”
Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery
Liu, Y.-H., Wang, Y.-R., Xiang, Y., Zhou, H.-D., Giunta, B., Mañucat-Tan, N. B., Tan, J., Zhou, X.-F., & Wang, Y.-J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8694-9 · Cited by 99
Amyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
on behalf of the MEMENTO cohort Study Group, Dufouil, C., Dubois, B., Vellas, B. J., Pasquier, F., Blanc, F., Hugon, J., Hanon, O., Dartigues, J., Harston, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0288-0 · Cited by 105
“Early diagnosis and intervention are therefore a priority target to defeat late-onset Alzheimer’s disease and related disorders (ADRD); however, the causes remain unknown, and no curative treatment is therefore available.”
BackgroundInfluentialAdvances in non-dopaminergic treatments for Parkinson's disease
Stayte, S., & Vissel, B. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00113 · Cited by 125
Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells
Kwon, K., & Daniell, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.115 · Cited by 102
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
“On the basis of this, four Phase 3 trials commenced; two of the completed trials failed to show a clinical improvement, and the other trials were discontinued (Salloway et al., 2014).”
BackgroundImmunotherapy for Parkinson’s disease
Schwab, A. D., Thurston, M. J., Machhi, J., Olson, K. E., Namminga, K. L., Gendelman, H. E., & Mosley, R. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104760 · Cited by 110
Taylor, X., Clark, I. M., Fitzgerald, G. J., Oluoch, H., Hole, J. T., DeMattos, R. B., Wang, Y., & Pan, F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00649-w · Cited by 94
“Bapineuzumab, a humanized form of murine monoclonal antibody 3D6, was the first antibody used for passive immunotherapy in late-stage clinical trials for AD, recognizing the linear N-terminus of Aβ and binding all forms of Aβ including prefibrillar aggregates and plaques [3].”
BackgroundEvaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease
Chouraki, V., for the International Genomics of Alzheimer’s Project, Reitz, C., Maury, F., Bis, J. C., Bellenguez, C., Yu, L., Jakobsdottir, J., Mukherjee, S., Adams, H. H., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150749 · Cited by 98
Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology
Zou, P., Wu, C., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00385-7 · Cited by 97
“…to date, nearly all of the interventions targeting Aβ and tau protein hyper-phosphorylation in AD have failed in phase III clinical trials [193–195], including immunotherapies, drugs reducing Aβ production or enhancing Aβ clearance, as well as drugs inhibiting tau phosphorylation or…”
BackgroundSex differences in Alzheimer’s disease: Understanding the molecular impact
Toro, C. A., Zhang, L., Cao, J., & Cai, D. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.031 · Cited by 98
Randomized controlled trial of TDCS on cognition in 201 seniors with mild neurocognitive disorder
Lu, H., Chan, S. S. M., Chan, W. C., Lin, C., Cheng, C. P. W., & Linda Chiu Wa, L. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50823 · Cited by 96
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
Dominantly Inherited Alzheimer Network, Ringman, J. M., Goate, A., Masters, C. L., Cairns, N. J., Danek, A., Graff-Radford, N., Ghetti, B., & Morris, J. C. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0499-8 · Cited by 96
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 97
“Notably, recent data obtained with anti-A antibodies in Phase 3 trials indicate at least partial efficacy in some biomarker and cognition measures in mild to moderate AD patients (Doody et al., 2014; Salloway et al., 2014).”
BackgroundMolecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Crespi, G. A. N., Hermans, S. J., Parker, M. W., & Miles, L. A. (2015) · Scientific Reports · doi:10.1038/srep09649 · Cited by 96
“Tomaselli, S., et al. The alpha-to-beta conformational transition of Alzheimer’s Abeta-(1-42) peptide in aqueousmedia is reversible: a step by step conformational analysis suggests the location of beta conformation seeding.”
BackgroundGenetic variants in Alzheimer disease — molecular and brain network approaches
Gaiteri, C., Mostafavi, S., Honey, C. J., De Jager, P. L., & Bennett, D. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.84 · Cited by 96
Karakatsani, M. E., Kugelman, T., Ji, R., Murillo, M., Wang, S., Niimi, Y., Small, S. A., Duff, K. E., & Konofagou, E. E. (2019) · Theranostics · doi:10.7150/thno.28717 · Cited by 98
“Clinically, several phase III trials have been performed in patients with mild-to-moderate Alzheimer’s disease but failed to show significant improvement in their primary outcomes [10,11].”
BackgroundResting State fMRI and Improved Deep Learning Algorithm for Earlier Detection of Alzheimer’s Disease
Guo, H., & Zhang, Y. (2020) · IEEE Access · doi:10.1109/access.2020.3003424 · Cited by 110
“AD can be diagnosed with fMRI data [7], [8].”
BackgroundInterplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer’s Disease
Llanos-González, E., Henares-Chavarino, Á. A., Pedrero-Prieto, C. M., García-Carpintero, S., Frontiñán-Rubio, J., Sancho-Bielsa, F. J., Alcain, F. J., Peinado, J. R., Rabanal-Ruíz, Y., & Durán-Prado, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01444 · Cited by 96
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis
Yassine, H. N., Feng, Q., Azizkhanian, I., Rawat, V., Castor, K., Fonteh, A. N., Harrington, M. G., Zheng, L., Reed, B. R., DeCarli, C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1924 · Cited by 94
Fourier, A., Portelius, E., Zetterberg, H., Blennow, K., Quadrio, I., & Perret-Liaudet, A. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.024 · Cited by 94
Self-citationVascular risk factors and Alzheimer’s disease
O’Brien, J. T., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0218-y · Cited by 93
“Several therapeutic attempts to affect underlying disease processes, based on modifying deposition and/or clearance of amyloid or tau, are underway, although unfortunately initial clinical trials, largely around reducing deposition of amyloid, have been largely negative [2].”
BackgroundDoré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
Self-citationExosomes in neurologic and psychiatric disorders
Tsilioni, I., Panagiotidou, S., & Theoharides, T. C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.005 · Cited by 93
Gao, C., Chu, X., Gong, W., Zheng, J., Xie, X., Wang, Y., Yang, M., Li, Z., Gao, C., & Yang, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00626-1 · Cited by 93
RetractedRecent Applications of Retro-Inverso Peptides
Doti, N., Mardirossian, M., Sandomenico, A., Ruvo, M., & Caporale, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168677 · Cited by 89
“Also, no significant improvements in terms of reduction of symptoms and immunological adverse reactions in patients [108] were observed with bapineuzumab, a humanized anti-Aβ1–42 monoclonal antibody (mAb).”
BackgroundAmyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · PubMed Central · Cited by 138
ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease
Wang, B.-J., Her, G. M., Hu, M.-K., Chen, Y.-W., Tung, Y.-T., Wu, P.-Y., Hsu, W.-M., Lee, H., Jin, L.-W., Hwang, S.-P. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618804114 · Cited by 91
Mo, J., Li, J., Yang, Z., Liu, Z., & Feng, J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.469 · Cited by 90
“Salloway et al.(36) described the information of ARIA, mortality, AEs in detail.”
BackgroundMethodInfluentialOno, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92
“In contrast, other clinical trials of monoclonal antibodies targeting fibrillar Aβ, such as bapineuzumab [63], or soluble monomeric Aβ, such as solanezumab [20], have failed to produce clinical effects.”
ResultDetecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Guo, T., Landau, S. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000009216 · Cited by 95
Farahzadi, R., Fathi, E., & Vietor, I. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00052 · Cited by 91
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 93
How early can we diagnose Alzheimer disease (and is it sufficient)?: The 2017 Wartenberg lecture
Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006088 · Cited by 89
Boada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91
“On the other hand, even within the amyloid hypothesis, a potential explanation of the Abrelated failures is that a relevant Ab species is insufficiently affected, which is not the case of PE because it affects all Ab species [54].”
BackgroundNew fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 91
Echeverria, V., Yarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 91
Yao, L., Gu, X. Q., Song, Q., Wang, X., Huang, M., Meng, H., Hou, L., Kang, T., Chen, J., Chen, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.055 · Cited by 93
MicroRNA-302 switch to identify and eliminate undifferentiated human pluripotent stem cells
Parr, C., Katayama, S., Miki, K., Kuang, Y., Yoshida, Y., Morizane, A., Takahashi, J. B., Yamanaka, S., & Saito, H. (2016) · Scientific Reports · doi:10.1038/srep32532 · Cited by 96
Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 97
“Furthermore, Ab immunotherapies showed little cognitive benefit in mild-to-moderate AD patients (Doody et al. 2014; Salloway et al. 2014).”
BackgroundThe informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“Despite the scientific strength of the amyloid hypothesis, to date clinical trials targeting Aβ have failed to clearly demonstrate clinical benefit [14, 36] with the consequence that the amyloid hypothesis has been questioned [7, 40, 41].”
BackgroundGuercio, B. J., Donovan, N. J., Munro, C. E., Aghjayan, S. L., Wigman, S. E., Locascio, J. J., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150146 · Cited by 88
“Despite significant efforts to develop such therapies, few clinical trials have shown clinically significant benefit (3-5).”
Self-citationClioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse
Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., & Bush, A. I. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.015 · Cited by 93
“clinical trials targeting -amyloid aggregation, a key feature of AD, were conducted, but failed to demonstrate efficiency (3-5).”
BackgroundMattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
“This mismatch between the clinical diagnosis and Ab biomarkers seems especially prevalent in APOE ε4 noncarriers, as illustrated by a clinical trial in which 36% of APOE ε4-negative patients with a diagnosis of “AD dementia” lacked Ab pathology as determined by PET [19].”
Self-citationTargeting microglia for the treatment of Alzheimer’s disease
McGeer, P. L., & McGeer, E. G. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 88
“These include bapineuzumab, directed against Ab 1-6 [70], solanezumab [71], directed at the midregion of Ab, and ponezumab [72], which binds specifically to the C-terminus regions of Ab.”
BackgroundThe landscape of metabolic brain alterations in Alzheimer's disease
Batra, R., Arnold, M., Wörheide, M. A., Allen, M., Wang, X., Blach, C., Levey, A. I., Seyfried, N. T., Ertekin‐Taner, N., Bennett, D. A., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12714 · Cited by 93
A systematic review: Virtual-reality-based techniques for human exercises and health improvement
Ali, S. G., Wang, X., Li, P., Jung, Y., Bi, L., Kim, J., Chen, Y., Feng, D. D., Magnenat‐Thalmann, N., Wang, J., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1143947 · Cited by 102
“This suggests that by the time symptoms appear, neuronal death and neuropathology have already had a significant impact on the brain, severely limiting the efficacy of these drugs (77).”
Satlin, A., Wang, J., Logovinsky, V., Berry, S., Swanson, C., Dhadda, S., & Berry, D. A. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
Vasudev, A., Shariff, S. Z., Liu, K., Burhan, A. M., Herrmann, N., Leonard, S., & Mamdani, M. (2015) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.07.001 · Cited by 95
“Fortunately, it is possible to reduce potentially inappropriate combination therapy through concerted multidisciplinary and frequent medication reviews.(46) In light of the limitations posed by pharmacological treatments, nonpharmacological interventions using music or environmental manipulation may provide alternativ…”
BackgroundMolecular imaging in dementia: Past, present, and future
Laforce, R., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
“[141] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M,”
BackgroundTomioka, I., Ishibashi, H., Minakawa, E. N., Motohashi, H. H., Takayama, O., Saito, Y., Popiel, H. A., Puentes, S., Owari, K., Nakatani, T., et al. (2017) · eNeuro · doi:10.1523/eneuro.0250-16.2017 · Cited by 91
Abushouk, A. I., Elmaraezy, A., Aglan, A., Salama, R., Fouda, S., Fouda, R., & AlSafadi, A. M. (2017) · BMC Neurology · doi:10.1186/s12883-017-0850-1 · Cited by 84
“Future trials are recommended to incorporate amyloid thresholds in their eligibility criteria [16].”
BackgroundMethodResultInfluentialDuan, Y., Lu, L., Chen, J., Wu, C., Liang, J., Zheng, Y., Wu, J., Rong, P., & Tang, C. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0864-6 · Cited by 96
Loeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
Biomarkers in the diagnosis and management of Alzheimer’s disease
Wurtman, R. J. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.034 · Cited by 97
“[19] Salloway S, Sperling R, Fox NC, et al.”
The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Salem, N., Vandal, M., & Calon, F. (2015) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.10.003 · Cited by 85
Clark, I. A., & Vissel, B. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13181 · Cited by 84
“If, on the other hand, HMGB1 and the S100s – as well as other inflammation-enhancing DAMPs of which we are as yet unaware – are plentiful, immunotherapeutically removing soluble Aβ, no matter how diligently or on how grand a scale, as in recent random trials (Doody et al., 2014; Salloway et al., 2014), is unlikely to…”
BackgroundUwajeh, P. C., Iyendo, T. O., & Polay, M. (2019) · EXPLORE · doi:10.1016/j.explore.2019.05.002 · Cited by 119
Wang, L., & Mao, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052360 · Cited by 97
“However, higher doses may lead to increased occurrence of side effects like microhemorrhages that have been observed during clinical trials [124,133].”
BackgroundYang, J., Li, S., He, X.-B., Cheng, C., & Le, W. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0106-3 · Cited by 83
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
Ashton, N. J., Nevado-Holgado, A. J., Barber, I. S., Lynham, S., Gupta, V., Chatterjee, P., Goozee, K., Hone, E., Pedrini, S., Blennow, K., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau7220 · Cited by 82
Self-citationTwo decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 83
Brody, A. H., & Strittmatter, S. M. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 86
“Finally, while immunotherapy with antibodies raised against Aβ has been shown to reduce plaque burden in AD patients, such interventions have failed to improve patient outcome (Doody et al., 2013, 2014; Holmes et al., 2008; Salloway et al., 2014; reviewed by Spires-Jones & Hyman, 2014).”
BackgroundMonsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82
“The CSF AD core biomarker concentrations (p-tau181, t-tau, and Aβ1-42) were quantified by commercially available enzyme-linked immunosorbent assays (INNOTEST β-AMYLOID [1-42], INNOTEST hTAU Ag, and INNOTEST PHOSPHO-TAU [181P]; Fujirebio Europe).”
MethodSelf-citationJeremic, D., Navarro-López, J. D., & Jiménez-Díaz, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102012 · Cited by 77
Avgerinos, K. I., Manolopoulos, A., Ferrucci, L., & Kapogiannis, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-75204-8 · Cited by 95
“Overall, nine studies were at low risk of bias 4,6,22,24,25,30 , one at high risk 27 , and seven were deemed as having some concerns 5,23,26–28 .”
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
“We expect that future investigations will provide an empirical basis for optimizing their joint use.”
Self-citationAmyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
Marr, R. A., & Hafez, D. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00187 · Cited by 83
“…antibodies, such as bapineuzumab and solanezumab, Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 187 | 1 have failed to reach their desired cognitive endpoints in trials of mild/moderate AD (Salloway et al., 2009, 2014; Farlow et al., 2012; Doody et al., 2014).”
Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?
Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81
“The humanized monoclonal antibody bapineuzumab reduced amyloid depositions in the brain but did not improve the primary cognitive outcomes in phase II trials and led to adverse events including reversible vasogenic cerebral edema in MRI scans (68).”
Egan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0520-1 · Cited by 81
δ-secretase in neurodegenerative diseases: mechanisms, regulators and therapeutic opportunities
Zhang, Z., Tian, Y., & Ye, K. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-019-0179-3 · Cited by 77
“Unfortunately, they have thus far failed to produce effects that are clinically significant [32] [33] [34] [35] .”
BackgroundPotential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases
Drzezga, A., Barthel, H., Minoshima, S., & Sabri, O. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.129254 · Cited by 81
“Recent antiamyloid trials investigating monoclonal antibody therapies in patients with early Alzheimer disease did not successfully reach their predefined endpoints (53).”
Background
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.